67 patents
Utility
Compounds and Uses Thereof for the Modulation of Hemoglobin
12 Oct 23
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
Filed: 4 Nov 22
Utility
Urea Derivatives As Pyruvate Kinase Activators
7 Sep 23
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
Lina Q. Setti, Brian Cathers, Zhe Li, Shahul Nilar, James Partridge, Chul Yu, Ming Yu, Manuel Zancanella
Filed: 3 Aug 21
Utility
Cycloalkyl pyrimidines as ferroportin inhibitors
5 Sep 23
The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I′ and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
Qing Xu, Carsten Alt, Zhe Li, Shahul Nilar, Peter Michael Rademacher, Calvin Wesley Yee
Filed: 28 Apr 21
Utility
Substituted Benzaldehyde Compounds and Methods for Their Use In Increasing Tissue Oxygenation
17 Aug 23
Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Brian Metcalf, Chihyuan Chuang, Jeffrey Warrington, Matthew P. Jacobson
Filed: 20 Apr 23
Utility
Histone methyltransferase inhibitors
1 Aug 23
Ming Yu, Zhe Li
Filed: 4 Nov 20
Utility
Methods of Use for Pyrimidines As Ferroportin Inhibitors
20 Jul 23
The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
Qing Xu, Carsten Alt, Zhe Li, Shahul Nillar, Peter Michael Rademacher, Calvin Wesley Yee
Filed: 28 Apr 21
Utility
Process for Synthesizing 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)-PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
13 Jul 23
Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes.
Zhe Li, Nathan Guz, Yiyang Shao, Julieana Cocuz, Markus Frieser, George Petros Yiannikouros, Liang Liao
Filed: 25 Aug 22
Utility
Tricyclic compounds as histone methyltransferase inhibitors
30 May 23
The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease).
Zhe Li, Ming Yu, Qing Xu, Manuel Zancanella
Filed: 13 Aug 18
Utility
Modulators of Hemoglobin
25 May 23
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
Zhe Li
Filed: 21 Nov 22
Utility
Pyrrolidine-pyrazoles As Pyruvate Kinase Activators
25 May 23
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
Ming Yu, Brian Edwin Cathers, Zhe Li, Brian Walter Metcalf, Lina Q. Setti, Chul Yu, Manuel Zancanella
Filed: 31 Mar 21
Utility
Thieno Pyrimidines As Ferroportin Inhibitors
25 May 23
The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
Qing Xu, Zhe Li, Shahul Nilar
Filed: 28 Apr 21
Utility
Pyrrolidine-pyrazoles As Pyruvate Kinase Activators
18 May 23
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
Lina Q. Setti, Shahul Nilar, Zhe Li, Ming Yu, Manuel Zancanella
Filed: 17 Jan 23
Utility
Tricyclic compounds as histone methyltransferase inhibitors
21 Feb 23
Ming Yu, Zhe Li, Qing Xu, Calvin Yee, Lina Setti, Hing Sham
Filed: 13 Aug 18
Utility
Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
31 Jan 23
Lina Q. Setti, Shahul Nilar, Zhe Li, Ming Yu, Manuel Zancanella
Filed: 7 Feb 22
Utility
Methods of Administering Voxelotor
19 Jan 23
Provided herein are methods of using voxelotor for the treatment of sickle cell disease in patients also having severe hepatic impairment.
Carla B. Washington
Filed: 17 Nov 20
Utility
Modulators of hemoglobin
10 Jan 23
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
Zhe Li
Filed: 4 May 20
Utility
Tricyclic Compounds As Histone Methyltransferase Inhibitors
5 Jan 23
The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease).
ZHE LI, MING YU, QING XU, MANUEL ZANCANELLA
Filed: 13 Aug 18
Utility
Compounds and Uses Thereof for the Modulation of Hemoglobin
22 Dec 22
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
Filed: 12 Aug 22
Utility
Compounds and uses thereof for the modulation of hemoglobin
20 Dec 22
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
Filed: 21 Sep 20
Utility
Crystalline Polymorphs of the Free Base of 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
15 Dec 22
Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N.
Zhe Li, Stephan D. Parent, Travis Houston
Filed: 10 Aug 22